Delavirdine mesylate - Generic Drug Details

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What are the generic drug sources for delavirdine mesylate and what is the scope of freedom to operate?

Delavirdine mesylate is the generic ingredient in one branded drug marketed by Viiv Hlthcare and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Delavirdine mesylate has twenty-five patent family members in twenty countries.

One supplier is listed for this compound.

Summary for delavirdine mesylate

International Patents:	25
US Patents:	1
Tradenames:	1
Applicants:	1
NDAs:	1
Suppliers / Packagers:	1
Bulk Api Vendors:	38
Clinical Trials:	18
Patent Applications:	3,636
Formulation / Manufacturing:	see details
DailyMed Link:	delavirdine mesylate at DailyMed

Recent Clinical Trials for delavirdine mesylate

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Agouron Pharmaceuticals	N/A
National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2
Bristol-Myers Squibb	Phase 2

See all delavirdine mesylate clinical trials

Pharmacology for delavirdine mesylate

Drug Class	Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor
Mechanism of Action	Non-Nucleoside Reverse Transcriptase Inhibitors

Medical Subject Heading (MeSH) Categories for delavirdine mesylate

Anti-HIV Agents
Reverse Transcriptase Inhibitors

Synonyms for delavirdine mesylate

1-(3-(Isopropylamino)-2-pyridyl)-4-((5-methanesulfonamidoindol-2-yl)carbonyl)piperazine monomethanesulfonate
1-[3-[(1-Methylethyl)amino]-2-pyridinyl]-4-[[5-[(methylsulfonyl)amino]-1H-indol-2-yl]carbonyl]-piperazine monomethanesulfonate
136817-59-9 (Parent)
147221-93-0
3575AH
421105KRQE
AC1L9B2V
AKOS024458004
BCP09460
C08087
CHEBI:4379
CHEMBL929
CS-1661
D00895
Delavirdine (mesylate)
Delavirdine (mesylate) pound>>U 90152
Delavirdine mesilate
Delavirdine mesilate (JAN)
Delavirdine mesylate (USAN)
Delavirdine mesylate [USAN]
Delavirdine mesylate, >=98% (HPLC)
delavirdine methanesulfonate
Delavirdine monomethanesulfonate
FT-0603116
HY-10571A
J-008332
methanesulfonic acid; N-[2-[4-[3-(propan-2-ylamino)pyridin-2-yl]piperazine-1-carbonyl]-1H-indol-5-yl]methanesulfonamide
MFCD00866948
MolPort-006-823-811
N-(2-(4-(3-(isopropylamino)pyridin-2-yl)piperazine-1-carbonyl)-1H-indol-5-yl)methanesulfonamide methanesulfonate
N-[2-({4-[3-(propan-2-ylamino)pyridin-2-yl]piperazin-1-yl}carbonyl)-1H-indol-5-yl]methanesulfonamide methanesulfonate
N-[2-[[4-[3-[(1-Methylethyl)amino]-2-pyridinyl]-1-piperazinyl]carbonyl]-1H-indol-5-yl]methanesulfonamide mesylate
N-[2-[[4-[3-[(1-Methylethyl)amino]-2-pyridinyl]-1-piperazinyl]carbonyl]-1H-indol-5-yl]methanesulfonamide Methanesulfonate
N-{2-[4-(3-Isopropylamino-pyridin-2-yl)-piperazine-1-carbonyl]-1H-indol-5-yl}-methanesulfonamide; compound with methanesulfonic acid
Rescriptor
Rescriptor (TN)
SCHEMBL40522
SR-05000001471
SR-05000001471-2
U-90152S
U-90152T
UNII-421105KRQE

US Patents and Regulatory Information for delavirdine mesylate

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Viiv Hlthcare	RESCRIPTOR	delavirdine mesylate	TABLET;ORAL	020705-001	Apr 4, 1997		DISCN	Yes	No	Start Trial	Start Trial				Start Trial
Viiv Hlthcare	RESCRIPTOR	delavirdine mesylate	TABLET;ORAL	020705-002	Jul 14, 1999		RX	Yes	Yes	Start Trial	Start Trial				Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for delavirdine mesylate

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Viiv Hlthcare	RESCRIPTOR	delavirdine mesylate	TABLET;ORAL	020705-001	Apr 4, 1997	Start Trial	Start Trial
Viiv Hlthcare	RESCRIPTOR	delavirdine mesylate	TABLET;ORAL	020705-001	Apr 4, 1997	Start Trial	Start Trial
Viiv Hlthcare	RESCRIPTOR	delavirdine mesylate	TABLET;ORAL	020705-002	Jul 14, 1999	Start Trial	Start Trial
Viiv Hlthcare	RESCRIPTOR	delavirdine mesylate	TABLET;ORAL	020705-002	Jul 14, 1999	Start Trial	Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for delavirdine mesylate

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
Hungary	0102206	Start Trial
Slovenia	1083885	Start Trial
Denmark	1083885	Start Trial
Japan	4827296	Start Trial
China	1301149	Start Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

By using our website you are consenting to our use of cookies in accordance with our privacy policy.